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Abstract
IBD is a chronic and relapsing inflammatory disorder of the gut that demands long-lasting treatment
targeting both flare-up periods andmaintenance of remission. Oral systemic steroids have been used
to induce remission in patients with active IBD for over 50 years due to their potent anti-
inflammatory effects. The efficacy of systemic steroids in this setting has been largely
demonstrated. However, the wide range of adverse events associated with these drugs has
prompted the development of equally effective but less toxic steroid compounds. Currently,
topically acting oral steroids are an important therapeutic option for Crohn's disease, ulcerative
colitis andmicroscopic colitis, being oral budesonide and oral beclomethasone established elements
of the IBD armamentarium. At present, oral budesonide is the first-line therapy to induce remission
in microscopic colitis and mild to moderate ileocaecal CD patients and oral beclomethasone is
effective treating mild to moderate UC patients with left-sided or extensive disease. This review
aims at evaluating the current role of these compounds in IBD clinical practice.
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After antibiotics, most gastroenterologists would choose
corticosteroid treatment as the second major advance in
drug therapy during the first half of the twentieth century.1
Following the demonstration of their therapeutic effects in
rheumatoid arthritis in the late 1940s,2 corticosteroids were
rapidly introduced in inflammatory bowel disease (IBD) arma-
mentarium. Although advances in general medical care could
have contributed to the mortality decline of an acute attack of
ulcerative colitis (UC) after the 1950s, the introduction of
corticosteroid therapy in IBD undoubtedly played amajor role in
improving UC mortality.3 Corticosteroids offer a high rate of
clinical response and remission in both UC and Crohn's disease
(CD), but their introduction is often associated with severe
adverse effects that limit their long-term use.4–6
The administration of corticosteroids induces a variety
of changes in the normal metabolism. Clinicians must always
bear in mind that the choice of dose, route and duration of
therapy impacts clinical efficacy but also determines the
severity of the subsequent side-effects. In the individual
level, many factors also influence the safety profile of
steroids such as the genetic background, the endocrine and
nutritional status and the disease itself or other concomitant
comorbidities.7 The most noticeable side-effects associated
with systemic steroids use include glaucoma, fluid retention,
increased blood pressure, weight gain, diabetes, loss of bone
calcium and an increased risk for infections.8
In this context, an ideal corticosteroid therapy theoret-
ically should be as potent as classical systemic corticoste-
roids, but with an improved safety profile. In recent years,
new corticosteroid molecules have been developed for IBD
management combining three major characteristics: an
oral controlled-release formulation that can reach different
bowel segments, high affinity for the corticosteroid receptor
affording potent local efficacy and an important first-pass liver
metabolism.9 These so-called topically acting oral steroids
are characterized by a low systemic bioavailability aimed atminimizing the amount of drug that reaches the systemic
circulation. As a result, these relatively new drugs manage
to achieve an enhanced safety profile without significant loss
of therapeutic effectiveness.9,10
Oral budesonide and beclomethasone are two fine
examples of oral locally acting steroids used in IBD clinical
practice. Oral budesonide has become first-line therapy to
induce remission inmild tomoderate ileocaecal CD patients and
oral beclomethasone has its role in treating mild to moderate
UC activity. This review aims at evaluating the current role of
these compounds in IBD clinical practice.
2. Budesonide
Budesonide is a synthetic steroid that has high topical
glucocorticoid activity with low systemic bioavailability caused
by a high first-pass hepatic metabolism. Budesonide has a
superior side-effect profile to conventional steroid therapy
because of its relatively low bioavailability, and is better able to
preserve adrenal function and bone mass. Superior tolerability
might be attributed to extensive first-pass metabolism of
budesonide by cytochrome P450 3A (CYP3A) enzymes and to
gastrointestinal effluxmediated by P-glycoprotein, a product of
the multidrug resistance 1 gene (MDR1).11,12
2.1. Efficacy of budesonide for induction of remission
in CD
2.1.1. Budesonide vs. placebo
Greenberg et al. in a double-blind, multicentre trial with
258 patients compared the efficacy of budesonide 3, 9, or
15 mg daily with placebo.13 After eight weeks of treatment,
remission occurred in 51% of patients receiving 9 mg of
budesonide (43% and 33% with 15 and 3 mg, respectively) as
compared to 20% of those receiving placebo (Pb0.001).
Subsequently, Tremaine et al. published a multicentre,
double blind, randomized trial with 200 patients with mild to
Table 1 Studies comparing oral budesonide with conventional steroids for induction of remission at 8 weeks.
Author n Drugs Remission (%) Main conclusions
Rutgeerts (19) 176 Budesonide (9mg)
Prednisolone (40mg)
53
65
Prednisolone no superior to budesonide
Bar-Meir (20) 201 Budesonide (9mg)
Prednisone (40mg)
51
52
Budesonide is as effective as prednisone
Gross (21) 67 Budesonide (9mg)
Methylprednisolone (48mg)
56
73
Budesonide is as effective as methylprednisolone
Campieri (22) 178 Budesonide (9mg)
Prednisone (40mg)
60
60
Budesonide is as effective as prednisone
Escher (23) 48 Budesonide (9mg)
Prednisolone (1mg/kg/day)
55
71
No significant differences between the two groups
Van Ierssel (24) 18 Budesonide (9mg)
Prednisolone (40mg)
56
89
No significant differences between the two groups
Levine (26) 33 Budesonide (9mg)
Prednisone (40mg)
47
50
Budesonide is as effective as prednisone
Seow a (15) 750 Budesonide
Conventional steroids
52
61
Budesonide is less effective than conventional steroids
a Seow et al. performed a meta-analysis including a total of 750 patients in 8 trials. The global rates are related to remission after
8 weeks. Budesonide was demonstrated to be inferior to conventional steroids for the induction of remission in active CD.
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comparing budesonide 9 mg once daily, 4.5 mg b.i.d. and
placebo for 8 weeks.14 Remission was achieved in 48%, 53%,
and 33% of patients with 9 mg, 4.5 mg b.i.d and placebo,
respectively. Differences were not significant but the mean
change from the baseline Crohn's disease activity index
(CDAI) between combined budesonide and placebo groups
was significant (pb0.05). In a recent Cochrane review
that included these two previously referred studies, authors
showed that, after 8 weeks of treatment, budesonide was
significantly more effective than placebo for induction of
remission in CD (RR 1.96, 95% CI 1.19 to 3.23).152.1.2. Budesonide vs. mesalamine
Budesonide and mesalamine were compared in a double-
blind, multicentre trial with 182 CD patients.16 Patients
were randomized to receive budesonide 9 mg once daily or
mesalamine 2 g b.i.d for 16 weeks. Remission rates after
8 weeks of treatment were 69% in the budesonide group and
45% in the mesalamine group (P=0.001); the respective rates
after 16 weeks of treatment were 62% and 36% (Pb0.001). In
another publication, the same authors observed that budeso-
nide (9 mg once daily) improves health-related quality of life
to a greater extent than mesalamine (2 g b.i.d.) in patientsTable 2 Studies comparing oral budesonide with conventional ste
at 8 weeks.
Author n Drugs Remission
(%)
Main conc
Gross
(21)
67 Budesonide (9mg)
Methylprednisolone (48mg)
40
60
Budesoni
Campieri
(22)
178 Budesonide (9mg)
Prednisone (40mg)
23
54
Budesoni
Seow a
(15)
48 Budesonide (9mg)
Conventional steroids
27
57
Budesoni
induction
a Seow et al. is a meta-analysis which included both studies evaluatiwith mild to moderate active CD.17 In the recent Cochrane
review, authors have shown that budesonide was significantly
more effective than mesalamine for induction of remission
(RR 1.63; 95% CI 1.23 to 2.16).15 Recently, Tromm et al.
performed a randomized, double-blind, 8-week, multicentre
study in which 309 patients with mild to moderately active
CD received pH-modified-release oral budesonide (9 mg/day
once daily or 3 mg/day t.i.d) or Eudragit-L-coated oral mesa-
lamine (4.5 g/day).18 Clinical remission at the final visit
occurred in 69.5% of patients given budesonide vs. 62.1% with
placebo, evidencing that budesonide is at least as effective as
mesalamine to induce remission in mild to moderate CD.
Clinical remission rates did not differ significantly between
the two budesonide groups.2.1.3. Budesonide vs. other corticosteroids
Based on the idea that budesonide presents an improved
safety profile compared to conventional steroids, several
studies have been performed in order to compare the efficacy
of these drugs (Table 1).19–26 In the Cochrane review, 9 studies
comparing budesonide with conventional corticosteroids were
included and itwas observed that budesonidewas significantly
less effective than conventional steroids for induction of
remission (RR 0.86, 95% CI 0.76 to 0.98). Conventional steroidsroids for induction of remission in patients with severe activity
lusions
de is inferior to methylprednisolone in severe activity
de is less effective than prednisone in severe patients
de is clearly less effective than conventional corticosteroids for
of remission
ng budesonide in severe CD.
Table 3 Studies comparing oral budesonide with placebo for maintenance of remission at 12 months.
Author Drugs Remission
(%)
Main conclusions
Ferguson (28) Budesonide (6 mg)
Placebo
52
40
Relapse rate and time to relapse were similar in the patients treated with
budesonide and placebo
Greenberg (29) Budesonide (6 mg)
Placebo
39
33
Budesonide prolonged remission, but this effect was not sustained at 12 months
Hanauer (30) Budesonide (6 mg)
Placebo
53
42
Relapse rates were not significantly different at the 1-year end point
Hellers (31) Budesonide (6 mg)
Placebo
68
35
The frequency of endoscopic recurrence did not differ between the groups
Lofberg (32) Budesonide (6 mg)
Placebo
41
37
Budesonide did not have any clear impacton the overall relapse rate after 12 months
Benchimol a(33) Budesonide (6 mg)
Placebo
55
48
Budesonide is no better than placebo at maintaining remission at 12 months
a The study by Benchimol et al. is a meta-analysis including previous studies evaluating budesonide as maintenance therapy.
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severe disease (CDAIN300) (RR 0.52, 95% CI 0.28 to 0.95),
suggesting that locally active oral corticoids have limited
usefulness in this setting (Table 2). Importantly, fewer adverse
effects occurred in patients treated with budesonide com-
pared to those treatedwith conventional steroids (RR 0.64, 95%
CI 0.54 to 0.76). Similarly, budesonide preserved better the
adrenal function than conventional steroids (RR for abnormal
ACTH test 0.65, 95% CI 0.55 to 0.78).152.2. Efficacy of budesonide in maintenance of
remission in CD
Approximately 50% of patients achieving remission with con-
ventional corticosteroids are not able to maintain remission
after 1 year.27 In addition, conventional steroids are not used
as maintenance treatment due to their well-known adverse
effects. The more positive safety profile of budesonide has
encouraged some investigators to attempt to identify whether
budesonide could be effective as CD maintenance treatment,
unfortunately achieving poor results (Table 3).28–32 A recent
Cochrane review evaluating eight studies that compared
budesonide with placebo concluded that budesonide 6 mg
daily was no more effective than placebo for maintenance of
remission at 3 months (RR 1.25; 95% CI 1.00 to 1.58; P=0.05),
6 months (RR 1.15; 95% CI 0.95 to 1.39; P=0.14), or 12 months
(RR 1.13; 95% CI 0.94 to 1.35; P=0.19).33
In contrast, in a prospective, investigator-blind, one year
trial that compared efficacy of budesonide and mesalamine
as maintenance treatment, Mantzaris et al. observed that the
1-year relapse rate was significantly lower in the budesonide
group than in the mesalamine group (55% vs. 82%; 95% CI,
12.4%–41%; P=0.045). Compared with mesalamine, budeso-
nide treatment was also associatedwith a better quality of life
throughout the study (P=0.0001).34 Tursi et al. in a small
prospective study also suggested that budesonide could be a
reasonable alternative as maintenance treatment for CD
patients.35 In this study, 14 out of 20 patients maintained
remission after a mean follow-up of 25 months without
significant side-effects. Nevertheless, in keeping with the
Cochrane review, the ECCO guidelines states that budesonidemay delay relapse after medically induced remission, but is
not effective at maintaining remission for 12 months.6
2.3. Efficacy of budesonide for prevention of
postsurgical recurrence in CD
A double-blind, multicentre, randomized trial evaluating
budesonide utility to prevent CD postsurgical recurrence
compared budesonide (6 mg) to placebo.31 The frequency of
endoscopic recurrence did not differ between groups at 3
and 12 months. Another multicentre randomized double-
blind placebo-controlled trial was performed comparing
3 mg oral pH-modified release budesonide to placebo.36
The recurrence rate after 1 year was 57% in the budesonide
group and 70% in the placebo group, not reaching statistical
significance. Authors concluded that low-dose oral budeso-
nide cannot be recommended for prevention of postopera-
tive relapse in CD.
2.4. Budesonide in pregnancy and paediatric CD
There is no standard medical CD management during preg-
nancy and there is limited data regarding safety and efficacy of
budesonide in this scenario. In a recent retrospective study, 6
patients with budesonide 6 mg daily and 2 patients with 9 mg
daily were evaluated.37 The average treatment duration ranged
from 1 to 8 months. There were no cases of maternal adrenal
suppression, glucose intolerance, ocular side effects, hyper-
tension or fetal congenital abnormalities. Indirect data from
inhaled or intranasal budesonide have confirmed that this drug
is not associated with adverse fetal outcomes.38
Conventional steroids side-effects such us osteoporosis and
growth retardation are especially detrimental in paediatric
patients. Two studies have compared budesonide and con-
ventional steroids for induction of remission in children and
they concluded that there were not significant differences in
efficacy between both drugs.23,26 Recently, a randomized,
controlled, double-blind study in 70 children with mild or
moderately active CD was performed.39 Authors compared
two different budesonide doses (standard dose of 9 mg daily
for 7 weeks followed by 6 mg daily for an additional 3 weeks
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by the same regimen as the first group). At week 7, clinical
response was obtained in 51.4% 9 mg group versus 74.3% in
the 12 mg group. There was no significant difference in re-
mission rates, frequency of adverse events or serum cortisol.
ECCO guidelines states that budesonide is effective and must
be favoured over prednisolone in mild to moderate active
ileocaecal paediatric CD.40
2.5. Budesonide for induction of remission in
ulcerative colitis (UC)
Although a first randomized, double-blind, controlled trial
comparing budesonide 10 mg and prednisolone 40 mg in left
side UC did show differences in remission rates,41 posterior
studies have not been able to reproduce these results. A
Cochrane review stated that oral budesonide was significantly
less likely to induce clinical remission than oral mesalamine
after 8 weeks of therapy (RR 0.72, 95% CI 0.57 to 0.91) and
there was no significant benefit from oral budesonide in
comparison with placebo for inducing clinical remission after
4 weeks of treatment (RR 1.41, 95% CI 0.59 to 3.39).42
More recent studies, however, have suggested that bude-
sonide can be useful in the management of UC patients. In a
randomized, double-blind, multicentre study comparing 3 g
mesalamine with 9 mg budesonide for achieving remission in
mild-to-moderately active UC, budesonide was inferior to
mesalamine but achieved clinical remission in almost 40% of
patients with a rapid onset of resolution.43
Another study evaluated the efficacy and safety of the
newly developed Budesonide-MMX® 9 mg tablets (a new oral,
extended-release formulation) in 36 left-sided UC patients.44
After 4 weeks, 47.1% in the budesonide-MMX® group achieved
remission whereas only 33.3% in the placebo group, neverthe-
less differences did not reach statistical significance due
to the small number of patients included. More recently, in
two large multicenter clinical trials comparing once daily
budesonide MMX® 9 mg and 6 mg tablets to placebo over
an 8-week treatment, a significantly greater proportion of
patients achieved remission in the 9 mg group compared to
placebo.45,46 Currently the role of budesonide MMX® as
induction treatment for UC patients is still matter of debate.
In this regard, though the compound seems to be more
effective than placebo in mild tomoderate active UC patients,
comparison with effective induction doses of mesalamine is
still lacking.
2.6. Budesonide for maintenance of remission in
ulcerative colitis (UC)
Based on the better results of the newer budesonide MMX®
as induction treatment for active mild to moderate UC
patients in multicenter trials,45,46 Sandborn et al. evaluated
the role of this compound as maintenance treatment in a
12 month placebo-controlled trial.47 In this study, 122 patients
were randomized to either Budesonide-MMX®6 mg or placebo.
The probability of clinical relapse at 12 months was reduced
and the median time to clinical relapse was longer in the
intention-to-treat population with budesonide-MMX® 6 mg
compared to placebo. Currently, the role of budesonide as
maintenance treatment for UC patients requires future furtherevaluation since there is still very limited data and no com-
parison with mesalamine is available at this time.2.7. Budesonide in chronic refractory pouchitis
Almost half of the patients who have undergone ileal pouch-
anal anastomosis surgery for UC will develop at least one
episode of pouchitis. Up to 15% of patients with pouchitis
experience a chronic course. In that scenario, antibiotics are
less effective and maintenance therapy may be required.48
Combined antibiotic therapy or biologics may be effective
but new therapeutic options are needed.48–50 Oral budeso-
nide was evaluated in two small prospective open-label
studies as a treatment alternative for chronic refractory
pouchitis, both achieving good remission rates.51,52 In the
largest study, 20 consecutive patients with active pouchitis
with no response to antibiotic treatment were treated with
oral budesonide 9 mg/day for 8 weeks. In this series, 15 of 20
patients (75%) achieved clinical and endoscopic remission.51
Currently, 8-week treatment with oral budesonide appears
effective in inducing remission in patients with chronic
refractory pouchitis but further studies are needed.2.8. Budesonide in microscopic colitis (MC)
There have been relatively few randomised controlled trials
assessing treatment options both in induction of remission
and maintenance therapy in MC. Budesonide is the most
evaluated treatment for MC patients and it has proven efficacy
in inducting remission in both collagenous and lymphocytic
colitis. Three short-term (6–8 weeks), randomized controlled
trials have consistently shown that budesonide 9 mg daily for
6–8 weeks is superior to placebo in collagenous colitis, with
most patients (80%) achieving remission within 2–4 weeks.53–55
In a recent Cochrane meta-analysis that included these studies,
clinical response occurred in 81% of patients receiving budeso-
nide compared to 17% of patients with placebo (pb0.00001).
The pooled odds ratio for clinical response with budesonide
treatment was 12.32 (95% CI 5.53 to 27.46), with a number
needed to treat of 2 patients.56 Recently, in a new large
double-blind, randomized, multicenter trial of budesonide in
collagenous colitis, budesonide achieved 80% of clinical
remission over 60% in the placebo group, suggesting once
more that budesonide is highly effective for induction of
remission in collagenous colitis, improving both stool frequency
and consistency.57
Few randomized, controlled trials have investigated the
efficacy of pharmacological treatment for lymphocytic colitis.
Three randomized trials evaluating the role of budesonide
treatment in this scenario have shown that this drug is
effective for inducing clinical response (OR 9.00; 95% CI
1.98–40.93), with an NNT of 3 patients.56 In addition, a new
randomized, placebo-controlled trial in forty-two patients
with lymphocytic colitis receiving budesonide 9 mg daily
for 6 weeks found that 86% of patients given budesonide
were in clinical remission compared with 48% of patients
given placebo (p=0.010).58 Although budesonide is the best-
documented short-term treatment for lymphocytic colitis, an
optimal long-term budesonide therapy in this setting needs
further evaluation.
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six months. It is possible that in some patients doses could be
individualized from 3 mg every other day to 9 mg daily.59
The pooled odds ratio for maintenance of clinical response in
clinical trials with 6 mg daily was 8.82 (95% CI 3.19–24.37)
with an NNT of 2 patients.56 Time to relapse is usually brief
for patients who relapse, approximately two weeks. Long-
term maintenance therapy with oral budesonide is effective;
nevertheless the risk of relapse after 24–30 weeks of treat-
ment is similar to that observed after induction treatment.59
3. Beclomethasone
Beclomethasone was first introduced into the UC armamen-
tarium as a rectal suspension enema for the treatment
of distal UC with good efficacy when compared to 5-ASA
enemas or topic conventional steroids.60–66 More recently,
beclomethasone was formulated as an oral enteric coated
compound to be released in the distal small bowel and
throughout the colon. Rizzello et al. undertook a dose-finding
study comparing doses of 5 and 10 mg. Oral beclomethasone
was associated with a significant clinical, endoscopic and
histological benefit after 4 weeks of treatment.67 In addition,
the 5 mg dose was better tolerated and induced lower
reduction of plasma cortisol levels, being equivalent to the
10 mg dose in terms of clinical efficacy. Therefore, at present,
the recommended label dose of oral beclomethasone to
induce remission in mild to moderate UC patients is 5 mg/day.
3.1. Beclomethasone vs. mesalamine in UC
Three studies have evaluated the effectiveness of oral
beclomethasone to treat active UC patients compared to
5-ASA compounds (Table 4). Campieri et al. compared oral
beclomethasone 5 mg and 5-ASA 2.4 g in a 4-week multi-
centre, randomized, single-blind study. Both groups achieved
similar global remission rates but remission was more fre-
quently obtained with beclomethasone than 5-ASA in the
subgroup of extensive UC patients.68 Rizzello et al. published
a 4-week, double-blind, placebo-controlled study in which
patients with left-sided or extensive UC were randomized to
receive oral 5-ASA (3.2 g/d) along with beclomethasone
(5 mg/d) or placebo.69 The combination of oral beclometha-
sone with 5-ASA proved to be significantly more effective
than 5-ASA alone. Importantly, in this study, beclomethasone
presented a good safety profile with no inhibition of pituitary-
adrenal function detected. In an open-labeled, randomized
study in a pediatric population, 30 patients with active UCTable 4 Studies comparing oral beclomethasone (BDP) to oral 5
Author n Drugs Remiss
(%)
Rizzello (69) 119 5-ASA (3.2 g/day) plus BDP (5 mg/day)
5-ASA (3.2 g/day) plus placebo
59
34
Campieri
(68)
177 BDP (5 mg/day)
5-ASA (2,4 g/day)
63
63
Romano (70) 30 BDP (5 mg/day)
5-ASA (80 mg . kg . day)
80
33(left-sided or pancolitis) were enrolled to receive either oral
beclomethasone (5 mg/day) for 8 weeks, followed by mainte-
nance therapy with oral mesalazine or 80 mg.kg of 5-ASA.70
Patients treated with beclomethasone showed a significant
reduced clinical activity within 4 weeks with 80% achieving
clinical remission compared with 33% treated with only 5-ASA.
Importantly, in 73% of beclomethasone-treated patients
colonoscopy showed remission compared to 27% of 5-ASA
(Pb0.025). These studies suggest that beclomethasone is an
option as induction therapy for mild to moderate extensive or
left-sided colitis. Of note, oral beclomethasone is currently
not indicated to treat neither ulcerative proctitis nor severe
disease activity because its efficacy in these settings was
not evaluated by controlled studies.
3.2. Beclomethasone in UC patients not responding
to mesalamine
In the scenario when patients do not respond to induction
treatment with 5-ASA, oral systemic steroids are usually the
next option. The existence of many steroid-related adverse
effects prompted the evaluation of oral beclomethasone in
the specific setting. In that regard, Papi et al. studied the
role of beclomethasone in patients with mild to moderately
active UC not responding to 5-ASA.71 A 4-week course of
oral 10 mg/day beclomethasone was followed by a 4-week
administration of 5 mg/day in 64 UC patients in which 5-ASA
had previously failed. The authors found a remission rate of
75% with most patients achieving 1-year maintenance of
remission with no need for further steroid treatment. These
data suggest that oral beclomethasonemight have a role as an
alternative to systemic steroids in patients with a mild to
moderate flare that is not responsive to 5-ASA. Importantly,
Papi et al. achieved these impressive remission rates using a
4-week course of 10 mg/day at induction which is twice the
recommended label dose.
3.3. Beclomethasone vs. conventional steroids in UC
Balzano et al.72 evaluated the efficacy of oral beclometha-
sone and oral prednisone in a mild to moderately active UC
population, in an 8-week, multicentre, randomized, double-
blind study.72 Both drugs achieved comparable clinical and
endoscopic efficacy, with oral beclomethasone presenting
less steroid-related adverse effects. Out of the context of
controlled clinical trials, data suggests that oral beclo-
methasone also manages to achieve impressive remission
rates. In a very recently published, large retrospective study-ASA for induction of clinical remission in UC.
ion Main conclusions
Oral BDP+oral 5-ASA is more effective than 5-ASA alone
Oral BDP is as effectiveas 5-ASA
Oral BDP is more effective than 5-ASA in inducing
remission
189Oral locally active steroids in inflammatory bowel diseaseaiming at evaluating oral beclomethasone efficacy in the
clinical practice scenario, oral beclomethasone induced
remission in more than 40% and response in two thirds of UC
patients. In addition, patients with left-sided or extensive,
mild or moderately active UC treated for more than 4 weeks
presented the best outcome.733.4. Beclomethasone as induction therapy for Ileal
CD
In an open-label, budesonide-controlled, randomized study,
30 patients with active ileal or right colon non-stricturing non-
penetrating disease was enrolled to receive either budesonide
9 mg/day or oral beclomethasone 10 mg/day for 8 weeks.74 In
the budesonide group, 67% of the patients achieved remission
after 8 weeks of treatment compared to 53% of remission rate
in the beclomethasone group suggesting that beclomethasone
seems to be less effective than budesonide as induction treat-
ment. As this study remains the only prospective evaluation of
beclomethasone as induction therapy, its role in the manage-
ment of active ileal CD patients remains uncertain.3.5. Beclomethasone as maintenance therapy for
Ileal CD
At present, oral budesonide is the first-line therapy to
induce remission in mild to moderate ileocaecal CD, but this
topically active agent failed to be effective as an alternative
therapy to maintain patients relapse-free at 1 year. This
prompted the evaluation of other locally active steroids as
maintenance treatment for CD patients. In that regard,
Astegiano et al. published a small retrospective study evaluat-
ing oral beclomethasone as maintenance therapy in mild to
moderate CD patients.75 In this study, beclomethasone man-
aged to achieve clinical response at 24 weeks in 67% and
maintained remission in 94% of the patients who were in
remission at baseline. Subsequently, Pratera et al. published
the first randomized, double-blind, placebo-controlled, multi-
centre study assessing the efficacy of beclomethasone in the
treatment of ileal Crohn's disease as maintenance therapy.76
This study included a total of 84 CD patients with active ileitis,
ileoceacal disease and right colitis. After having received
prednisone, 73 patients who achieved remission were random-
ized to receive beclomethasone or placebo. In the beclometha-
sone group, patients received 15 mg/day for 2 weeks and
afterwards, 10 mg/day. The placebo group continued predni-
sone for 2 weeks and then placebo. At 24 weeks, significantly
less patients in the beclomethasone group compared to the
placebo presented disease activity (23.3% vs. 53.8%). The
cumulative probability of relapse was also significantly lower in
patients on beclomethasone than on placebo (38% vs. 56%). Due
to the small sample size, this study has to be interpreted with
caution and further studies are required to establish the
effectiveness of oral beclomethasone as an alternative main-
tenance therapy for CD patients. As stated by Billioud et al.,
beclomethasone might be used as maintenance therapy in CD
patients who are intolerant, refractory or with a contraindi-
cation to standard immunosuppressive therapy, as well as to
reduce exposure to systemic steroids in case of steroid
dependency.774. Conclusion
Oral systemic steroids have been used to induce remission in
patients with active IBD for over 50 years due to their potent
anti-inflammatory effects. Nevertheless, the wide range of
adverse events associated with these drugs has prompted
the development of less toxic steroid compounds.
These oral locally active drugs have improved safety
profile and constitute an important alternative to the classic
steroids for patients with mild to moderate active CD and UC
as induction treatment. In this regard, oral budesonide and
beclomethasone can replace systemic corticoids in mild to
moderate ileocaecal CD and mild to moderate left-sided or
extensive UC, respectively. In addition, oral budesonide has
been proven to be highly effective in the management of
microscopic colitis.
In case of severe disease activity, locally active steroids
should not be used. In this scenario, either systemic corticoids
are more effective or the usefulness of these newer com-
pounds was not properly assessed by clinical trials.
Importantly, as maintenance treatment, budesonide is no
more effective than placebo in CD at 12 months of follow-up
and beclomethasone still has to be evaluated by controlled
prospective studies.
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